Britain’s National Institute of Clinical Excellence (NICE), which provides guidance to health professionals, patients and the public on best practices in medicine, last month recommended the use of drug-eluting stents in patients with symptomatic coronary artery disease. NICE recommended that drug-eluting stents be used in all patients at high risk of restenosis caused by the body overreacting to the insertion of a coronary stent with an inflammatory response and tissue growth. Such high-risk patients include those with naturally smaller arteries or in whom a longer section of the artery is blocked.